Fed’s Powell opens door to potential rate cuts at Jackson Hole
On Thursday, Cantor Fitzgerald reaffirmed its Overweight rating on Surgery Partners shares (NASDAQ:SGRY), maintaining a price target of $36.00, which aligns with the stock’s current trading price of $23.54. According to InvestingPro data, the company appears slightly undervalued based on its Fair Value analysis. The firm’s analysis of Surgery Partners’ data suggests two potential scenarios: the company is either outperforming its peers as positions and bonuses decrease quarter-over-quarter compared to peers that are stable or increasing, or hiring is slowing, which might indicate the likelihood of a pending offer being finalized.
Surgery Partners, a healthcare services company that operates surgical facilities with annual revenue of $3.1 billion and an EBITDA of $627 million, has been under scrutiny by market analysts looking to gauge its performance relative to industry peers. Cantor Fitzgerald’s recent review has led to the continuation of a positive outlook for the company’s stock, with no change to the price target. InvestingPro analysis reveals the company maintains a "GREAT" overall financial health score of 3.04 out of 5, suggesting solid fundamentals despite current market challenges.
The assessment by Cantor Fitzgerald indicates that Surgery Partners could be managing its resources more efficiently than its competitors, potentially leading to a more favorable financial position. This efficiency could be reflected in the reduction of positions and bonuses, which contrasts with the trend observed in other companies within the sector.
Alternatively, the firm notes that a slowdown in hiring at Surgery Partners may be a sign that the company is preparing for a significant corporate development. While the details of any such offer have not been disclosed, the implication is that an event of this nature could have a substantial impact on the company’s future.
Investors and market watchers often look to the guidance of research firms like Cantor Fitzgerald to make informed decisions. The maintained Overweight rating and price target suggest a continued confidence in Surgery Partners’ ability to perform well in the market.
As of the last trading session, Surgery Partners shares have not shown any significant movement following the analyst’s comments. The company’s stock performance will continue to be watched closely by investors as they consider Cantor Fitzgerald’s analysis and the potential outcomes it has presented. InvestingPro subscribers have access to 8 additional key insights about Surgery Partners, including detailed analysis of its growth prospects and valuation metrics. Get the complete picture with the comprehensive Pro Research Report, available exclusively to subscribers along with in-depth analysis of 1,400+ other US stocks.
In other recent news, Surgery Partners Inc reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an EPS of $0.44 compared to a forecast of $0.39. The company also exceeded revenue forecasts, reporting $864.4 million against the anticipated $827.9 million. Despite these positive results, Benchmark analysts adjusted the price target for Surgery Partners shares to $35 from the previous $40, while maintaining a Buy rating. UBS analysts also lowered their price target for the company to $34 from $38, citing recent divestitures and a consistent ~12.0x EV/EBITDA multiple as reasons for the revision, but they maintained a Buy rating.
KeyBanc analysts reiterated a Sector Weight rating for Surgery Partners, noting the company’s solid fourth-quarter performance, with same-store revenue growth of 5.6%, slightly above their projection of 5.0%. Surgery Partners has provided a 2025 EBITDA outlook that aligns with current market consensus. A significant development for the company is the ongoing proposal from Bain Capital to acquire all outstanding shares at $25.75 per share, which remains a central focus for investors. This proposal highlights the increased interest from private equity in the healthcare sector, emphasizing Surgery Partners’ attractiveness as an investment. The company continues to manage its portfolio actively, with strategic decisions being closely monitored by investors and analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.